3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
121
Lymphoma, Mantle-Cell
20
Leukemia
14
Lymphoma, Non-Hodgkin
13
Lymphoma, Follicular
11
Neoplasms
10
Leukemia, B-Cell
10
Waldenstrom Macroglobulinemia
9
Recurrence
9
Lymphoma, B-Cell
9
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia, Lymphoid
8
Lymphoma
7
Hematologic Neoplasms
7
Leukemia, Myeloid, Acute
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Bronchiolitis Obliterans Syndrome
5
Leukemia, Prolymphocytic
4
Burkitt Lymphoma
4
Leukemia, Hairy Cell
3
Chromosome 17 deletion
3
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic, B-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
blinatumomab
15
Cyclophosphamide
15
Cytarabine
14
Azacitidine
11
venetoclax
10
fludarabine
10
fludarabine phosphate
7
Methotrexate
7
Daunorubicin
7
Rituximab
6
Vincristine
5
Mercaptopurine
5
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Doxorubicin
3
Dexamethasone
3
Cladribine
3
Busulfan
3
Asparaginase
3
thymoglobulin
2
pembrolizumab
2
pegaspargase
2
nilotinib
2
midostaurin
2
daratumumab
2
Vindesine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
ibrutinib
×
Other hematologic neoplasm
×
Clear all
NCT02666898
2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2
Completed
135 enrolled